Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality.


Journal

Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655

Informations de publication

Date de publication:
24 08 2020
Historique:
received: 28 10 2019
revised: 20 12 2019
accepted: 24 01 2020
pubmed: 7 3 2020
medline: 29 7 2021
entrez: 6 3 2020
Statut: ppublish

Résumé

Blood pressure (BP) management in frail older people is challenging. An randomised controlled trial of largely non-frail older people found cardiovascular and mortality benefit with systolic (S) BP target <120 mmHg. However, all-cause mortality by attained BP in routine care in frail adults aged above 75 is unclear. To estimate observational associations between baseline BP and mortality/cardiovascular outcomes in a primary-care population aged above 75, stratified by frailty. Prospective observational analysis using electronic health records (clinical practice research datalink, n = 415,980). We tested BP associations with cardiovascular events and mortality using competing and Cox proportional-hazards models respectively (follow-up ≤10 years), stratified by baseline electronic frailty index (eFI: fit (non-frail), mild, moderate, severe frailty), with sensitivity analyses on co-morbidity, cardiovascular risk and BP trajectory. Risks of cardiovascular outcomes increased with SBPs >150 mmHg. Associations with mortality varied between non-frail <85 and frail 75-84-year-olds and all above 85 years. SBPs above the 130-139-mmHg reference were associated with lower mortality risk, particularly in moderate to severe frailty or above 85 years (e.g. 75-84 years: 150-159 mmHg Hazard Ratio (HR) mortality compared to 130-139: non-frail HR = 0.94, 0.92-0.97; moderate/severe frailty HR = 0.84, 0.77-0.92). SBP <130 mmHg and Diastolic(D)BP <80 mmHg were consistently associated with excess mortality, independent of BP trajectory toward the end of life. In representative primary-care patients aged ≥75, BP <130/80 was associated with excess mortality. Hypertension was not associated with increased mortality at ages above 85 or at ages 75-84 with moderate/severe frailty, perhaps due to complexities of co-existing morbidities. The priority given to aggressive BP reduction in frail older people requires further evaluation.

Sections du résumé

BACKGROUND
Blood pressure (BP) management in frail older people is challenging. An randomised controlled trial of largely non-frail older people found cardiovascular and mortality benefit with systolic (S) BP target <120 mmHg. However, all-cause mortality by attained BP in routine care in frail adults aged above 75 is unclear.
OBJECTIVES
To estimate observational associations between baseline BP and mortality/cardiovascular outcomes in a primary-care population aged above 75, stratified by frailty.
METHODS
Prospective observational analysis using electronic health records (clinical practice research datalink, n = 415,980). We tested BP associations with cardiovascular events and mortality using competing and Cox proportional-hazards models respectively (follow-up ≤10 years), stratified by baseline electronic frailty index (eFI: fit (non-frail), mild, moderate, severe frailty), with sensitivity analyses on co-morbidity, cardiovascular risk and BP trajectory.
RESULTS
Risks of cardiovascular outcomes increased with SBPs >150 mmHg. Associations with mortality varied between non-frail <85 and frail 75-84-year-olds and all above 85 years. SBPs above the 130-139-mmHg reference were associated with lower mortality risk, particularly in moderate to severe frailty or above 85 years (e.g. 75-84 years: 150-159 mmHg Hazard Ratio (HR) mortality compared to 130-139: non-frail HR = 0.94, 0.92-0.97; moderate/severe frailty HR = 0.84, 0.77-0.92). SBP <130 mmHg and Diastolic(D)BP <80 mmHg were consistently associated with excess mortality, independent of BP trajectory toward the end of life.
CONCLUSIONS
In representative primary-care patients aged ≥75, BP <130/80 was associated with excess mortality. Hypertension was not associated with increased mortality at ages above 85 or at ages 75-84 with moderate/severe frailty, perhaps due to complexities of co-existing morbidities. The priority given to aggressive BP reduction in frail older people requires further evaluation.

Identifiants

pubmed: 32133525
pii: 5775492
doi: 10.1093/ageing/afaa028
pmc: PMC7444671
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

807-813

Subventions

Organisme : Department of Health
ID : DRF-2014-07-177
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Geriatrics Society.

Références

BMC Med. 2012 Jan 11;10:4
pubmed: 22236397
JAMA. 2016 Jun 28;315(24):2673-82
pubmed: 27195814
Circulation. 2017 Jun 13;135(24):2357-2368
pubmed: 28432148
Vasc Health Risk Manag. 2008;4(6):1315-25
pubmed: 19337545
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):722-7
pubmed: 17634318
Age Ageing. 2016 May;45(3):353-60
pubmed: 26944937
Age Ageing. 2018 Jul 1;47(4):505-508
pubmed: 29788097
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Age Ageing. 2019 Sep 1;48(5):627-635
pubmed: 31165151
J Am Geriatr Soc. 2017 May;65(5):995-1003
pubmed: 28039870
BMJ. 2018 Aug 28;362:k3349
pubmed: 30154082
Age Ageing. 2018 Jul 1;47(4):545-550
pubmed: 29741555
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Curr Hypertens Rep. 2017 Jan;19(1):3
pubmed: 28091868
Age Ageing. 2019 May 1;48(3):380-387
pubmed: 30824915
J Am Coll Cardiol. 2016 May 24;67(20):2419-2440
pubmed: 27079335
JAMA Intern Med. 2018 Jan 1;178(1):93-99
pubmed: 29204655
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
BMJ. 2013 May 20;346:f2350
pubmed: 23692896
JAMA. 2015 Jul 14;314(2):170-80
pubmed: 26172896
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272

Auteurs

Jane A H Masoli (JAH)

Epidemiology and Public Health Group, University of Exeter Medical School, Exeter, UK.
Department of Healthcare for Older People, Royal Devon and Exeter Hospital, Exeter, UK.

Joao Delgado (J)

Epidemiology and Public Health Group, University of Exeter Medical School, Exeter, UK.

Luke Pilling (L)

Epidemiology and Public Health Group, University of Exeter Medical School, Exeter, UK.

David Strain (D)

Department of Healthcare for Older People, Royal Devon and Exeter Hospital, Exeter, UK.
Diabetes and Vascular Research, University of Exeter Medical School, Exeter, UK.

David Melzer (D)

Epidemiology and Public Health Group, University of Exeter Medical School, Exeter, UK.
UConn Center on Aging, University of Connecticut Health Center, Farmington CT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH